Tools for Decentralized Clinical Trials for Substance Use Disorder (R41/R42 Clinical Trials Optional)

Active
No
Status
Closed
Release Date
October 25th, 2023
Open Date
February 14th, 2024
Due Date(s)
March 14th, 2024
Close Date
March 15th, 2024
Topic No.
RFA-DA-25-051

Topic

Tools for Decentralized Clinical Trials for Substance Use Disorder (R41/R42 Clinical Trials Optional)

Agency

Department of Health and Human ServicesNational Institutes of Health

Program

Type: STTRPhase: BOTHYear: 2024

Summary

The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for the development of tools for decentralized clinical trials (DCT) for substance use disorder (SUD). The traditional approach to SUD clinical trials involves in-person visits at clinical trial sites, which can limit participation and retention due to factors such as travel time, stigma, and caregiving responsibilities. DCTs offer a solution by utilizing telehealth visits, remote monitoring, and local medication dispensing. However, there are gaps in the existing technology, such as the lack of wearable sensors for physiological measurement and home-use detection devices for quantifying substances of interest. Additionally, there is a need for a comprehensive system that facilitates data movement and communication with study participants. The research questions in this solicitation focus on the development of wearable devices, socially acceptable devices for SUD trials, software solutions for data handling, and systems capable of operating in low-bandwidth or rural areas. The Small Business Technology Transfer (STTR) program is offering Phase I and Fast Track funding opportunities to support the technical merit, feasibility, and commercial potential of the proposed research and development efforts. Successful projects are expected to attract strategic partners or investors for further commercialization.

Description

Substance use disorder (SUD) clinical trials traditionally perform recruitment, enrollment, interventions, as well as information collection at the clinical trial sites. In-person visits at the sites are used for screening, assignment to interventions, treatment or other intervention, follow up, as well as collection of information from participants and entering it in a database.

Some of the in-person site visits may also include dispensing of medications that are required to be taken in front of the staff, testing for the presence of investigational drugs and their metabolites in urine or other matrices, testing for illicit drugs, and measuring physiological parameters. Some trial designs may also include delivery of education or behavior modification therapies either to the patients or to the providers. Requirements for participants to be physically present at the study location may be limiting the diversity of the participants in the trials due to a variety of factors including, for example, time to travel to the center, loss of time from work, transportation issues, child and elder care responsibilities. The perception of stigma associated with participating in a SUD trial can also prevent participation. These factors often hamper engagement, recruitment, screening as well as retention in trials. In a survey of clinical trials participants, it was found that they most often dislike the location, the length of the visit and time commitment.

The limitations for clinical trials described above could be alleviated by utilizing decentralized clinical trials (DCT). DCTs allow for most of the visits to be converted into telehealth visits and/or phone calls. The monitoring, when needed, is done with equipment delivered to the patient's house or at local clinical laboratories and/or health care providers. Medical staff can occasionally make house calls for procedures. Medication or devices for interventions may be dispensed locally. The data are transmitted securely over standard communication channels (e.g., via internet, phone, mail). Informed consent may be also obtained remotely via electronic signatures. This approach may solve the commuting problem and decrease the loss of time from work and home care issues. Medication deliveries, done via standard courier services in compliance with the relevant laws, obfuscate the type of delivered drug, which preserves privacy and may help reduce the stigma of being seen to receive medications for SUD treatment. DCT also allows recruitment of patients from states that have a low number of centers and areas that are too far from such centers (e.g., rural or some tribal areas).

Still, there are gaps that prevent the utilization of DCT in substance use area. The existing wearable sensors for physiological measurement are infrequently used in SUD trials and may need further validation. Many of these devices do not have software interface conforming to Fast Healthcare Interoperability Resources (FAIR) standard through which the devices can transmit the data to the study center. There are no wearable or home-use detection devices on the market capable of measuring the concentration of substances of interest in SUD trials (e.g., methadone, buprenorphine, their metabolites, as well as the spectrum of illicit drugs and their metabolites). Existing test strips are designed to detect presence of drugs or metabolites, but do not quantify them. Most of the existing tests capable of quantification are intended for laboratory use.

There is also a need of a comprehensive system that creates and stores trusted records to facilitate data movement via secure sharing and consent. Such a system should be able to seamlessly function in areas with less connectivity. The decreased number of in-person visits necessitates expanded use of all methods for remote communication (calls, emails, text messages, MMS messages, written communications via USPS, etc.), to support adherence to the protocol. Therefore, there is a need for a unified system capable to track and report all instances of communications with study participants, while alleviating the burden on the research staff. Importantly, such a system should be able to handle the communication streams from all different sources and merge the existing and new solutions for DCT in a functioning structure.

Research Questions: This notice of funding opportunity (NOFO) solicits development of tools for DCT with the overall goal to increase participation, diversity and retention in SUD clinical trials. This may include, but is not limited to, the research and development of:

Wearable devices for measurement of opioids, stimulants as well as other illicit or misused drugs and their metabolites that can be used in the diagnosis or treatment of SUD Devices for use in SUD trials with socially acceptable form factor and mode of use (size, shape, appearance and placement that does not attract attention or induce stigma) Software solutions capable of handling all data streams (both from devices and SUD study participants) and providing interface to existing data collection systems for clinical trials to ensure interoperability ( plug-and-play use ) System capable of operating with low-bandwidth services or asynchronously to support SUD trials in rural or tribal areas Words Matter

Drug addiction is a chronic but treatable disorder with well-understood genetic and social contributors. The National Institute on Drug Abuse (NIDA) encourages preferred language that accurately describes addiction and substance use in all submitted materials without perpetuating stigma and bias. Research shows that using person-first language such as "person with a substance use disorder" instead of "substance abuser" or "addict" can reduce negative associations and punitive attitudes among clinicians and researchers. Instead, NIDA encourages the use of "addiction" or "substance use disorders" or other specific terminology, such as "opioid use disorders (OUDs)" or "cocaine use disorders". In addition to using person-first language, NIDA recommends avoiding the term "substance abuse" and its derivatives in favor of "use," "misuse," or "use disorder(s)" where appropriate. Similarly, "abuse potential" may be replaced with "addiction liability."

NIDA encourages using the term "medications for opioid use disorder" (MOUD) instead of "medication-assisted treatment" (MAT) or "opioid substitution therapy" (OST) when referring to medications prescribed for the treatment of OUD. The term MOUD appropriately frames these life-saving medications as effective, front line treatments. In contrast, the term MAT implies that medication should have a supplemental or temporary role in treatment. OST reinforces the misconception that MOUD "substitutes" one drug for another instead of supporting recovery. The terminology shift to MOUD aligns with the way other psychiatric medications are understood (e.g., antidepressants, antipsychotics) as critical tools central to a patient's treatment plan.

These small but powerful substitutions may help address stigma in patients and study participants, which research shows reduces willingness to seek and accept treatment, among other adverse health outcomes. For more information on preferred language in addiction care, visit NIDAMED: https://www.drugabuse.gov/nidamed-medical-health-professionals/health-professions-education/words-matter-terms-to-use-avoid-when-talking-about-addiction.

The Small Business Technology Transfer (STTR) program is a phased program.

An overall objective of the STTR program is to increase private sector commercialization of innovations derived from federally supported research and development.

The main objective in STTR Phase I is to establish the technical merit and feasibility of the proposed research and development efforts. In contrast, the STTR Phase II objective is to continue the R&D efforts to advance the technology toward ultimate commercialization.

Beyond the scope of this NOFO, it is anticipated and encouraged that the outcomes of successful STTR projects will help attract strategic partners or investors to support the ultimate commercialization of the technology as a publicly available product or service.

This NOFO invites two types of applications:

Phase I. The objective of Phase I is to establish the technical merit, feasibility, and commercial potential of the proposed R/R&D efforts and determine the quality of performance of the small business recipient organization before proceeding to Phase II.

Fast Track. In an NIH STTR Fast-track both Phase I and Phase II are submitted and reviewed as one application to reduce or eliminate the funding gap between phases. Fast-Track (Phase I/ Phase II) applications should include a clear rationale of the technical and commercial feasibility of the proposed approach and technology in the SUD area; demonstrate a high probability of commercialization; include specific, measurable, achievable, relevant, and time-bound milestone deliverables. It is important to clearly state the go / no-go milestone(s) that will determine transition to Phase II and indicate potential Phase III support/interest (non-SBIR) from future commercialization partners. The objective of Phase II (as a part of Fast Track applications) is to continue the R&D efforts initiated in Phase I to advance technologies to potential commercialization. Projects proposed for Phase II are based on the results achieved in Phase I (or equivalent) and aim to demonstrate scientific and technical merit and commercial potential. Therefore, will evaluate whether that investigators have established technical and commercial feasibility in Phase I and whether proposed milestones have been met before deciding on Phase II support.

Similar Opportunities

Developing Regulated Therapeutic and Diagnostic Solutions for Patients Affected by Opioid and/or Stimulants use Disorders (OUD/StUD) (R41/R42 Clinical Trial Optional)
Department of Health and Human Services
The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for the development of regulated therapeutic and diagnostic solutions for patients affected by opioid and/or stimulants use disorders (OUD/StUD). The current drug crisis surrounding OUD/StUD is a significant issue, with over 100,000 overdose deaths reported in a one-year period. The goal of this solicitation is to offer new medical products that can monitor, diagnose, and treat patients suffering from these disorders. The solicitation is open to small business companies that have developed or are developing FDA-regulated products for different indications and are interested in demonstrating their potential application in the OUD/StUD space. The research and development activities may fall into two areas: pharmacotherapeutics (small molecules and biologics) and medical therapeutic and diagnostic devices, including software as a medical device. The proposed projects should aim to address the needs of patients suffering from OUD/StUD and may include activities such as target identification, lead optimization, preclinical studies, formulation development, and clinical trials. The funding for these projects will be provided through the Small Business Innovation Research (SBIR) program, with Phase I and Phase II funding available. The application due dates are August 15, 2023, February 14, 2024, August 13, 2024, and February 14, 2025. For more information and to apply, interested parties can visit the grants.gov website or the solicitation agency URL provided.
Harnessing Artificial Intelligence and Polypharmacology to Discover Pharmacotherapeutics for Substance Use Disorders (R41/R42 Clinical Trials Not Allowed)
Department of Health and Human Services
The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for the topic of "Harnessing Artificial Intelligence and Polypharmacology to Discover Pharmacotherapeutics for Substance Use Disorders (R41/R42 Clinical Trials Not Allowed)". This solicitation aims to leverage AI/ML tools to identify pharmacotherapeutic development candidates with lower toxicity and higher efficacy for the prevention or treatment of substance use disorders (SUDs). The traditional drug discovery paradigm of single-target-based approaches has limitations in addressing the complex mechanisms and polysubstance use associated with SUDs. Polypharmacology, the study of how drug molecules interact with multiple targets, is emerging as a new paradigm for drug development in multifactorial diseases like SUDs. The use of AI/ML technologies trained in polypharmacology can enhance the discovery and development efforts for SUD pharmacotherapeutics by identifying the best targets, designing effective multi-target directed ligands (MTDLs), and predicting the effects of binding to multiple biological targets. The research objectives include identifying and validating disease targets, screening potential compounds, developing assays, synthesizing novel compounds, and conducting in vitro and in vivo studies. The Small Business Technology Transfer (STTR) program is a phased program, with Phase I focused on establishing technical merit and feasibility, and Phase II aimed at advancing the technology towards commercialization. The Fast Track option allows for the submission and review of Phase I and Phase II grant applications together, expediting the award decisions and funding for projects with high potential for commercialization.
Seeking Products to Address Social Needs impacting Substance Use Disorders (SUD) (R43/R44 Clinical Trial Optional)
Department of Health and Human Services
The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for the development of technologies to address health-related social needs that impact substance use disorders (SUD), excluding alcohol use disorder. The purpose of this funding opportunity is to support small business concerns in developing technologies for commercialization that can fill the service gaps in addressing SUD. The research objectives include developing products that reduce costs, time, and increase access in addressing health-related social needs such as housing instability, non-medical transportation, food insecurity, utility needs, and personal safety. The technologies can include physical devices, digital services, software, or non-physical/non-tangible products. The funding opportunity is open for applications until March 14, 2026, and offers both Phase I and Phase II funding options. Phase I focuses on establishing technical merit and feasibility, while Phase II aims to advance technologies towards commercialization. Applicants are encouraged to review the guidelines and adhere to the requirements applicable to their research.
Developing Regulated Therapeutic and Diagnostic Solutions for Patients Affected by Opioid and/or Stimulants use Disorders (OUD/StUD) (R43/R44 - Clinical Trial Optional)
Department of Health and Human Services
The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for the development of regulated therapeutic and diagnostic solutions for patients affected by opioid and/or stimulants use disorders (OUD/StUD). The current drug crisis involving opioids and stimulants has resulted in a significant number of deaths and a need for comprehensive solutions. This funding opportunity aims to support research and development activities for novel medical products that address the needs of patients suffering from OUD/StUD. The two areas of focus are pharmacotherapeutics (small molecules, biologics, natural products, etc.) and medical therapeutic and diagnostic devices (imaging technologies, therapeutic devices, diagnostic assays, etc.). The projects proposed should aim to establish technical feasibility, commercial potential, and the quality of performance of the small business awardee organization. The funding opportunity includes Phase I, Phase II, Fast Track, and Direct to Phase II applications. The deadline for applications is February 15, 2025. For more information and to apply, visit the grants.gov website or the solicitation agency URL provided.